TABLE 1.
In vitro potency of eravacycline and comparator antibiotics against each isolatea
| Isolate | ERV modal MIC | Comparator MIC (μg/ml) |
Genotype/phenotype | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| TGC | LZD | VAN | MEM | ETP | FEP | TZP | CIP | TOB | |||
| SA 156 | 0.03 | 0.125 | 4 | 1 | NA | NA | NA | NA | NA | NA | CA-MRSA |
| SA 426 | 0.25 | 0.5 | 2 | 1–2 | NA | NA | NA | NA | NA | NA | HA-MRSA |
| EC 373 | 0.25 | 0.25 | NA | NA | ≤0.063 | ≤0.016 | 0.25 | 128 | 16 | 2 | Non-ESBL |
| CF 26 | 0.125 | 0.25 | NA | NA | ≤0.063 | ≤0.016 | ≤0.063 | 1 | ≤0.016 | 1 | Inducible AmpC |
| EC C3-14 | 0.25 | 0.125 | NA | NA | 4 | 16 | >64 | >256 | 4 | 64 | Non-ESBL |
a
SA, S. aureus; EC, E. coli; CF, C. freundii; CA-MRSA, community-acquired methicillin-resistant S. aureus; HA-MRSA, hospital-acquired methicillin-resistant S. aureus; ESBL, extended-spectrum beta-lactamase; NA, not applicable; ERV, eravacycline; TGC, tigecycline; LZD, linezolid; VAN, vancomycin; MEM, meropenem; ETP, ertapenem; FEP, cefepime; TZP, piperacillin-tazobactam; CIP, ciprofloxacin; TOB, tobramycin.